Overview

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

Status:
RECRUITING
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD) on a background inhaled treprostinil.
Phase:
PHASE2
Details
Lead Sponsor:
Pulmovant, Inc.
Treatments:
Dry Powder Inhalers